![]() |
市場調查報告書
商品編碼
1520503
2024-2032 年尼古丁口香糖市場報告(按類型、應用、配銷通路和地區)Nicotine Gum Market Report by Type, Application, Distribution Channel, and Region 2024-2032 |
2023年全球尼古丁口香糖IMARC Group規模達16億美元。推動全球市場發展的因素有很多,包括戒菸措施和健康意識的提高、對方便的非處方(OTC)尼古丁替代療法的需求不斷成長,以及提高產品功效的技術創新。
主要市場促進因素:人們對吸菸相關健康風險的認知不斷提高,以及世界各地的各種戒菸舉措,正在成為成長誘導因素。
主要市場趨勢:對非處方(OTC)尼古丁替代療法的需求增加。再加上該產品在尋求戒菸的個人中的便利性和可及性的提高,正在支持市場的成長。
地理趨勢:報告顯示,由於注重健康的消費者數量不斷增加,北美在市場上享有領先地位。
競爭格局:尼古丁口香糖產業的頂級參與者包括英美菸草、Cambrex Corporation、葛蘭素史克、ITC Limited、強生服務、諾華、Perrigo、輝瑞、武田製藥公司等。
挑戰與機會:挑戰包括需要克服與戒菸輔助工具相關的社會恥辱,並確保對尼古丁口香糖在戒菸過程中的作用進行適當的教育。儘管如此,尼古丁口香糖市場最近的機會是技術進步和公司之間的合作,以解決與吸煙相關的健康問題。
戒菸措施和健康意識
全球減少吸煙的努力以及健康意識的提高正在推動市場擴張。隨著人們對吸菸相關健康風險的認知不斷提高,人們正在積極尋找有效的戒菸策略。尼古丁口香糖是一種戒菸輔助劑,可透過逐漸並受控制地釋放尼古丁來幫助使用者控制戒斷症狀。此外,醫療保健組織和監管機構的各種戒菸計畫也為尼古丁口香糖的需求創造了有利的氛圍。由於對公共衛生的重視以及消除吸菸的持續努力,人們擴大接受這種口香糖作為戒菸治療的重要組成部分,這正在推動市場的成長。 2023 年 4 月 11 日,衛生部長尼爾·奧布萊恩 (Neil O'Brien) 在政策交流會上就政府降低吸煙率和解決未成年人吸電子煙問題的計劃發表講話,
對非處方尼古丁替代療法的需求不斷成長
根據IMARC Group的數據,到 2023 年,全球非處方藥產業規模為 1,687 億美元。推動市場的主要因素之一是對非處方尼古丁替代藥物的需求不斷成長。這種口香糖是一種易於取得的非處方藥解決方案,使用戶無需處方即可自行治療。對於那些試圖在不尋求醫療幫助的情況下戒菸的人來說,這種口香糖之所以受歡迎,是因為它的可及性和易用性。人們在管理健康方面變得更加積極主動,這為尼古丁口香糖市場前景提供了積極的前景。此外,2024 年1 月24 日,在奧裡薩邦克塔克的Sri Ram Chandra Bhanja (SCB) 牙科學院和醫院進行的一項臨床試驗揭示了尼古丁替代療法(NRT) 與尼古丁替代療法(NRT)合併使用時的顯著療效,這是戒菸工作的重大突破。
技術進步與產品創新
尼古丁替代療法的配方和管理方面的持續技術改進和產品創新正在推動市場成長。尼古丁口香糖公司正在投入資金進行研發(R&D)活動,以提高產品的效能以及使用者體驗。由於增強的口味和獨特的輸送系統等創新,用戶正在採用這些口香糖。此外,加深對尼古丁成癮和戒斷過程的了解也有利於創造更有效的口香糖配方。對更有效的戒菸解決方案的需求不斷成長,推動了尼古丁口香糖市場的成長。除此之外,市場上的公司正在獲得公認機構的產品批准。例如,Perrigo Company plc (PRGO) 於2023 年5 月16 日獲得美國食品藥物管理局(FDA) 的尼古丁塗層薄荷含片2 毫克和4 毫克OTC 的最終批准。的消費者的戒斷症狀抽煙。此外,它將以零售商的商店品牌標籤進行銷售,作為與 Nicorette 塗層冰薄荷含片相當的產品。
IMARC Group提供了每個細分市場的主要尼古丁口香糖市場趨勢分析,以及 2024-2032 年全球、區域和國家層面的預測。我們的報告根據類型、應用和配銷通路對市場進行了分類。
該報告根據類型提供了詳細的市場細分和分析。其中包括 2 毫克尼古丁口香糖、4 毫克尼古丁口香糖和 6 毫克尼古丁口香糖。根據該報告,2 毫克尼古丁口香糖佔最大佔有率。
那些希望在戒菸過程中減少尼古丁攝取的人會發現 2 毫克類別是合適的選擇。 2 毫克尼古丁口香糖是控制戒斷症狀同時逐漸戒除尼古丁依賴的理想替代品,使其成為輕度至中度吸菸者的完美選擇。此外,建議需要逐步戒菸策略和處於戒菸早期階段的人們,以便能夠更規範地轉向無尼古丁的生活。
戒斷診所
醫療實踐
個人吸煙者
其他
醫療實踐佔據行業最大佔有率
報告還提供了基於應用程式的詳細市場細分和分析。這包括戒斷診所、醫療實踐、個人吸菸者等。報告稱,醫療實踐佔據了最大的市場佔有率。
尼古丁口香糖用於醫療環境中更全面的戒菸計劃。醫生可能會向患者推薦這種口香糖,作為個人化戒菸方案的一部分或在常規諮詢期間。尼古丁從口香糖中逐漸且受調節的釋放與基於證據的療法是一致的。在醫療實踐應用中,強調了醫療保健專業人員在幫助人們戒菸方面的重要性,以及使用尼古丁口香糖帶來的健康優勢和個人化幫助。
零售藥局
專賣店
網路商店
其他
零售藥局代表領先的細分市場
該報告根據配銷通路對市場進行了詳細的細分和分析。這包括零售藥局、專賣店、網路商店等。報告稱,零售藥局是最大的細分市場。
尼古丁口香糖在零售藥局很容易買到。尋找戒菸產品的消費者可以輕鬆地在家附近找到這些產品。這種口香糖很容易取得,藥劑師可以提供與藥物相關的建議,這使其成為那些尋求個人支持和快速獲得戒菸產品的人的首選。
北美洲
美國
加拿大
亞太
中國
日本
印度
韓國
澳洲
印尼
其他
歐洲
德國
法國
英國
義大利
西班牙
俄羅斯
其他
拉丁美洲
巴西
墨西哥
其他
中東和非洲
北美市場領先,佔據最大的尼古丁口香糖市場佔有率
該報告還對所有主要區域市場進行了全面分析,其中包括北美(美國和加拿大);亞太地區(中國、日本、印度、韓國、澳洲、印尼等);歐洲(德國、法國、英國、義大利、西班牙、俄羅斯等);拉丁美洲(巴西、墨西哥等);以及中東和非洲。報告稱,北美是尼古丁口香糖最大的區域市場。
由於戒菸努力強勁、健康意識提高以及龐大的消費者基礎,北美成為一個重要的市場。該地區擁有完善的醫療基礎設施和積極的監管措施,有助於這些口香糖作為首選戒菸輔助工具的普及。此外,在北美地區尋求有效戒菸解決方案的人數有所增加。除此之外,這些口香糖在零售藥局和網路商店等各種分銷管道上的廣泛供應,有助於增加尼古丁口香糖市場收入。 2024年3月18日,全球領先的合約開發製造組織(CDMO)Cambrex宣布提前一年完成為期5年、1億美元的投資策略。該項目將在其北美和歐洲藥物開發和製造網路的 70% 範圍內增加超過 150,000 平方英尺的產能和產能擴張,並將於 2024 年底完成。來解決與複雜分子相關的挑戰。
市場研究報告也對市場競爭格局進行了全面分析。也提供了所有主要公司的詳細資料。尼古丁口香糖產業的一些主要市場參與者包括英美菸草、Cambrex Corporation、葛蘭素史克、ITC Limited、Johnson & Johnson Services、諾華、Perrigo、輝瑞、武田製藥公司。
(請注意,這只是關鍵參與者的部分列表,報告中提供了完整列表。)
市場的主要參與者正在參與專注於產品創新、行銷和協作的策略性舉措。主要製造商持續進行研發投資,旨在提高產品配方的有效性和吸引力。這些公司利用技術進步來創造新穎的輸送機制、改進的口味和更好的味道掩蔽,滿足消費者的喜好並推動市場成長。此外,強力的行銷活動以及與醫療保健組織的合作夥伴關係有助於提高個人對戒菸益處的認知,同時擴大消費者基礎。行業利益相關者和監管機構之間的合作確保遵守健康標準並創造積極的市場環境。 2023 年 7 月 3 日,全球最大的獨立消費者健康企業 Haleon 考慮出售其尼古丁口香糖業務,旨在精簡業務。該公司正在與顧問合作,為其 Nicotinell 品牌的尼古丁口香糖尋找潛在的買家,該品牌的銷售額可能價值約 8 億美元。
The global nicotine gum market size reached US$ 1.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 2.4 Billion by 2032, exhibiting a growth rate (CAGR) of 4.21% during 2024-2032. There are various factors that are driving the global market, which include smoking cessation initiatives and heightened health awareness, rising demand for convenient over the counter (OTC) nicotine replacement therapies, and technological innovations for enhancing product efficacy.
Major Market Drivers: The increasing awareness about health risks associated with smoking, along with various smoking cessation initiatives worldwide, are acting as growth-inducing factors.
Key Market Trends: There is a rise in the demand for over the counter (OTC) nicotine replacement therapies. This, coupled with the enhanced convenience and accessibility of the product among individuals seeking to quit smoking, are supporting the market growth.
Geographical Trends: According to the report, North America enjoys a leading position in the market due to the rising number of health-conscious consumers.
Competitive Landscape: Top players in the nicotine gum industry are British American Tobacco, Cambrex Corporation, GlaxoSmithKline, ITC Limited, Johnson & Johnson Services, Novartis, Perrigo, Pfizer, Takeda Pharmaceutical Company, among many others.
Challenges and Opportunities: Challenges include the need to overcome social stigmas associated with smoking cessation aids and ensure proper education about the role of nicotine gum in the quitting process. Nonetheless, nicotine gum market recent opportunities are technological advancements and collaborations among companies to address smoking-related health issues.
Smoking Cessation Initiatives and Health Awareness
Global efforts to reduce smoking, along with rising health awareness, are propelling the market expansion. People are actively looking for effective strategies to quit smoking as awareness about health risks connected with smoking increases among them. Nicotine gum is a smoking cessation aid that helps users manage the symptoms of withdrawal by releasing nicotine gradually and under control. In addition, various smoking cessation programs by healthcare organizations and regulatory authorities has created a favorable atmosphere for nicotine gum demand. The rising acceptance of this gum as an essential component of smoking cessation treatments due to the emphasis on public health and the ongoing efforts to eliminate smoking is impelling the market growth. On 11 April 2023, Neil O'Brien, Health Minister, delivered a speech at Policy Exchange on government plans to cut smoking rates and tackle underage vaping,
Growing Demand for OTC Nicotine Replacement Therapies
As per the IMARC Group, in 2023, the size of the OTC medication industry worldwide was US$ 168.7 Billion. One of the main factors propelling the market is the rising demand for OTC nicotine replacement medicines. This gum is an easily available OTC solution that enables users to self-administer therapy without a prescription. This gum's popularity as a top option for people trying to stop smoking without seeking medical help is due to its accessibility and ease of usage. People are becoming more proactive in managing their health, which is offering a positive nicotine gum market outlook. Furthermore, on 24 January 2024, in a significant breakthrough for tobacco cessation efforts, a clinical trial conducted at Sri Ram Chandra Bhanja (SCB) Dental College and Hospital in Cuttack, Odisha, unveiled the remarkable efficacy of nicotine replacement therapy (NRT) when combined with behavioral therapy.
Technological Advancements and Product Innovation
Continuous technological improvements and product innovations in the formulation and administration of nicotine replacement therapies are bolstering the market growth. Nicotine gum companies are spending money on research and development (R&D) activities to enhance the effectiveness of product as well as user experience. Users are adopting these gums owing to innovations like enhanced flavors and unique delivery systems. In addition, enhanced understanding of nicotine addiction and withdrawal processes are benefiting in the creation of gum formulations that are more efficient. The escalating demand for more efficient smoking cessation solutions is bolstering the nicotine gum market growth. Besides this, companies in the market are getting product approvals from the recognized authorities. For instance, Perrigo Company plc (PRGO) received final approval from the Food Drug Administration (FDA) for nicotine coated mint lozenges 2 mg and 4 mg OTC on 16 May 2023. The product helps in reducing withdrawal symptoms in consumers who are trying to quit smoking. Moreover, it will be marketed under retailer's store brand labels as a comparable offering to Nicorette coated ice mint lozenge.
IMARC Group provides an analysis of the key nicotine gum market trends in each market segment, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on type, application, and distribution channel.
The report has provided a detailed breakup and analysis of the market based on the type. This includes 2 mg nicotine gum, 4 mg nicotine gum, and 6 mg nicotine gum. According to the report, 2 mg nicotine gum represented the largest segment.
Those looking to cut back on their nicotine intake during their journey to quit smoking can find 2 mg category a suitable choice. 2mg nicotine gum is an ideal alternative for controlling withdrawal symptoms while progressively weaning off nicotine dependence, making it the perfect choice among light to moderate smokers. Furthermore, it is advised for people who need a step-down strategy and in the early phases of quitting in order to enable a more regulated shift to a life free of nicotine.
Withdrawal Clinics
Medical Practice
Individual Smokers
Others
Medical practice holds the largest share of the industry
A detailed breakup and analysis of the market based on the application have also been provided in the report. This includes withdrawal clinics, medical practice, individual smokers, and others. According to the report, medical practice accounted for the largest market share.
Nicotine gums are used in more comprehensive smoking cessation programs in medical settings. Physicians may recommend this gum to patients as part of individualized smoking cessation regimens or during routine consultations. The progressive and regulated release of nicotine from the gum is consistent with evidence-based therapies. In the medical practice application, the importance of healthcare professionals in helping people quit is emphasized, along with the health advantages and individualized assistance that come with using nicotine gum.
Retail Pharmacies
Specialty Stores
Online Stores
Others
Retail pharmacies represent the leading market segment
The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes retail pharmacies, specialty stores, online stores, and others. According to the report, retail pharmacies represented the largest segment.
Nicotine gums are readily available at retail pharmacies. Consumers in search of smoking cessation products can easily locate them in close proximity to their homes. This gum is easily available and pharmacists can offer their advice related to medication, which makes it a favored option for those seeking person-to-person support and quick access to quit smoking products.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America leads the market, accounting for the largest nicotine gum market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for nicotine gum.
North America stands as a significant market due to robust smoking cessation efforts, heightened health awareness, and a substantial consumer base. The region has a well-established healthcare infrastructure and proactive regulatory measures that contribute to the popularity of these gums as a preferred smoking cessation aid. In addition, there is an increase in the number of individuals seeking effective solutions to quit smoking in the North America region. Besides this, the wide availability of these gum across various distribution channels including retail pharmacies and online stores, assists in increasing nicotine gum market revenue. On 18 March 2024, Cambrex, a leading global contract development and manufacturing organization (CDMO), announced the completion of a 5-year, US$ 100-Million-dollar investment strategy, one year ahead of schedule. The project adds more than 150,000 square-feet of capacity and capability expansions across 70% of its North American and European drug development and manufacturing network, which will be completed by the end of 2024. The investments span all scales of clinical and commercial drug substance manufacturing and include advanced technologies to solve for challenges related to complex molecules.
The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the nicotine gum industry include British American Tobacco, Cambrex Corporation, GlaxoSmithKline, ITC Limited, Johnson & Johnson Services, Novartis, Perrigo, Pfizer, Takeda Pharmaceutical Company.
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
Key players in the market are engaging in strategic initiatives that are focused on product innovation, marketing, and collaborative efforts. Continuous R&D investments by key manufacturers aim to enhance the effectiveness and appeal of the product formulations. These companies leverage technological advancements to create novel delivery mechanisms, improved flavors, and better taste masking, meeting consumer preferences and driving market growth. Moreover, robust marketing campaigns and partnerships with healthcare organizations contribute to the rising awareness about smoking cessation benefits among individuals while expanding the consumer base. Collaborative efforts between industry stakeholders and regulatory bodies ensure compliance with health standards and foster a positive market environment. On 3 July 2023, Haleon, the world's biggest standalone consumer health business, explored the sale of its nicotine gum business as it aims to streamline its business. The company is working with an adviser to find potential suitors for its Nicotinell brand of nicotine gum, which could be worth about US$ 800 Million in sales.